Bosch Packaging Technology on track
Global growth expected to continue
Growth at Bosch Packaging Technology continues at an above-average rate for the market. The company expects order books to peak at over 900 million euros in 2012. This will be accompanied by a twelve percent increase in annual sales. “All of the
available economic data indicates continued growth on a global scale,” reported Friedbert Klefenz, President of Bosch Packaging Technology, speaking at Achema in Frankfurt, the industry's leading exhibition for process technology. “We expect to see very dynamic developments in Asia, the Indian subcontinent, Latin America and Africa – especially in generics, which will significantly gain importance
compared to conventional brand-name drugs.”
The international position of Bosch Packaging Technology which currently generates about 90 percent of its sales outside of Germany, ensures increasing independence from regional economic fluctuations. At the same time, diversification in the pharmaceutical sector supports consistent expansion of the Bosch portfolio along the entire value chain. With the takeover of Eisai Co., Ltd. (now Eisai Machinery, Tokyo, Japan) in April 2012 and the acquisitions of Hüttlin GmbH (Schopfheim, Germany) and Manesty (now Bosch Packaging Technology Ltd., Knowsley, United Kingdom) in summer 2011, Bosch Packaging Technology further expanded its inspection and process technology portfolio.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Applera and Bio-Rad Enter Settlement Discussions over Patent Infringement Lawsuit

Seeing how cells work as never before

Bio-based coating for wood outperforms traditional synthetic options - Researchers turn a non-toxic residue into wood coating that resists abrasion, stain, and sunlight.
AMSBIO Announces US Office
Medicon Valley Academy and Norgenta North German Life Science Agency agree on cooperation in two projects
ThromboGenics Announces License Agreement with Bharat Biotech for Novel Thrombolytic Agent

Diamond ring architecture of a protein complex
Taurine deficiency in sperm causes male infertility
Researchers from BGU have generated a promising drug candidate for the treatment of Psoriasis
Novartis begins shipment of Fluvirin seasonal influenza vaccine for the U.S. market ahead of schedule - Providing 30 million doses of Fluvirin vaccine in the U.S., to support the annual seasonal influenza vaccination campaign
